A detailed history of Engineers Gate Manager LP transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 53,772 shares of BLUE stock, worth $418,883. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,772
Holding current value
$418,883
% of portfolio
0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.47 - $1.35 $25,272 - $72,592
53,772 New
53,772 $27,000
Q4 2023

Feb 14, 2024

BUY
$1.32 - $4.83 $88,537 - $323,967
67,074 Added 135.0%
116,759 $161,000
Q3 2023

Nov 14, 2023

BUY
$3.02 - $4.05 $150,048 - $201,224
49,685 New
49,685 $151,000
Q1 2023

May 15, 2023

BUY
$3.14 - $8.22 $737,319 - $1.93 Million
234,815 New
234,815 $746,000
Q2 2022

Aug 15, 2022

SELL
$2.94 - $5.23 $159,186 - $283,178
-54,145 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$4.07 - $10.6 $220,370 - $573,937
54,145 New
54,145 $263,000
Q4 2021

Feb 14, 2022

SELL
$8.96 - $16.31 $148,261 - $269,881
-16,547 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$11.24 - $21.0 $93,932 - $175,497
8,357 Added 102.04%
16,547 $316,000
Q2 2021

Aug 16, 2021

BUY
$18.04 - $22.09 $147,747 - $180,917
8,190 New
8,190 $262,000
Q1 2021

May 17, 2021

SELL
$16.59 - $33.89 $479,600 - $979,726
-28,909 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$27.5 - $37.92 $450,422 - $621,091
16,379 Added 130.72%
28,909 $1.25 Million
Q3 2020

Nov 16, 2020

SELL
$34.44 - $43.75 $36,506 - $46,375
-1,060 Reduced 7.8%
12,530 $676,000
Q2 2020

Aug 17, 2020

BUY
$27.12 - $45.97 $368,560 - $624,732
13,590 New
13,590 $830,000
Q1 2020

May 15, 2020

SELL
$26.16 - $63.5 $96,792 - $234,950
-3,700 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$46.96 - $61.67 $173,752 - $228,179
3,700 New
3,700 $325,000
Q3 2019

Nov 14, 2019

SELL
$59.47 - $93.1 $198,094 - $310,116
-3,331 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$75.84 - $105.21 $252,623 - $350,454
3,331 New
3,331 $424,000

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $601M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.